Novavax, like other companies, is working on an Omicron-tailored version of its vaccine. On Monday it also launched a booster dose study with participants from the North American trial who will receive a third dose of either Novavax or another vaccine. Vaccine-poor countries may eagerly take Novavax’s product, given its ease of use.

